全文获取类型
收费全文 | 2368篇 |
免费 | 137篇 |
国内免费 | 62篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 84篇 |
妇产科学 | 16篇 |
基础医学 | 351篇 |
口腔科学 | 44篇 |
临床医学 | 195篇 |
内科学 | 449篇 |
皮肤病学 | 172篇 |
神经病学 | 116篇 |
特种医学 | 369篇 |
外科学 | 224篇 |
综合类 | 31篇 |
一般理论 | 2篇 |
预防医学 | 91篇 |
眼科学 | 9篇 |
药学 | 139篇 |
中国医学 | 7篇 |
肿瘤学 | 255篇 |
出版年
2022年 | 24篇 |
2021年 | 29篇 |
2020年 | 31篇 |
2019年 | 25篇 |
2018年 | 51篇 |
2017年 | 20篇 |
2016年 | 37篇 |
2015年 | 44篇 |
2014年 | 47篇 |
2013年 | 94篇 |
2012年 | 88篇 |
2011年 | 77篇 |
2010年 | 70篇 |
2009年 | 94篇 |
2008年 | 79篇 |
2007年 | 120篇 |
2006年 | 87篇 |
2005年 | 83篇 |
2004年 | 62篇 |
2003年 | 50篇 |
2002年 | 62篇 |
2001年 | 56篇 |
2000年 | 45篇 |
1999年 | 53篇 |
1998年 | 84篇 |
1997年 | 92篇 |
1996年 | 117篇 |
1995年 | 74篇 |
1994年 | 67篇 |
1993年 | 62篇 |
1992年 | 37篇 |
1991年 | 39篇 |
1990年 | 44篇 |
1989年 | 66篇 |
1988年 | 57篇 |
1987年 | 52篇 |
1986年 | 66篇 |
1985年 | 52篇 |
1984年 | 17篇 |
1983年 | 22篇 |
1982年 | 19篇 |
1981年 | 16篇 |
1980年 | 15篇 |
1979年 | 11篇 |
1978年 | 17篇 |
1977年 | 14篇 |
1976年 | 16篇 |
1975年 | 17篇 |
1974年 | 6篇 |
1973年 | 9篇 |
排序方式: 共有2567条查询结果,搜索用时 62 毫秒
1.
Sebastian Mondaca Walid K. Chatila David Bates Jaclyn F. Hechtman Andrea Cercek Neil H. Segal Zsofia K. Stadler Anna M. Varghese Ritika Kundra Marinela Capanu Jinru Shia Nikolaus Schultz Leonard Saltz Rona Yaeger 《Clinical colorectal cancer》2019,18(1):e39-e52
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献2.
3.
4.
5.
6.
7.
8.
Leonidas JC; Berdon WE; Valderrama E; Neveling U; Schuval S; Weiss SJ; Hilfer C; Godine L 《Radiology》1996,198(2):377
9.
JC Sitek† M Loeb‡ JR Ronnevig¶ 《Journal of the European Academy of Dermatology and Venereology》2007,21(7):891-896
BACKGROUND: Since 1997, a number of trials have shown promising results in treating generalized vitiligo with narrowband ultraviolet B (UVB) both in adults and children. However, there is little knowledge concerning the duration and permanency of the treatment-induced repigmentation. OBJECTIVE: Our main objective was to perform a follow-up trial of successfully treated patients receiving narrowband UVB for generalized vitiligo. METHODS: We have investigated to what degree the treatment-induced repigmentation remains stable for up to 2 years post-treatment. We performed an initial open trial including 31 patients with generalized vitiligo. They received narrowband UVB thrice weekly for up to 12 months. Patients experiencing > 75% repigmentation were defined responders and were included in the follow-up trial. Responders were followed every 6 months for up to 2 years after cessation of treatment. We observed the pigmentation status and registered any changes indicating loss of pigmentation and relapse. RESULTS: Eleven of the 31 treated patients were included in the follow-up trial. Six patients had relapse and five patients had stable response 24 months after cessation of treatment. Four out of six relapses were within 6 months post-treatment. CONCLUSION: In our study population of 31 patients with generalized vitiligo, five patients (16%) experienced > 75% stable repigmentation 2 years after cessation of a treatment programme of up to 1 years narrowband UVB therapy. 相似文献
10.
Ongoing pregnancies after intracytoplasmic injection using cryopreserved testicular spermatozoa 总被引:4,自引:2,他引:2
Perraguin-Jayot S; Audebert A; Emperaire JC; Parneix I 《Human reproduction (Oxford, England)》1997,12(12):2706-2709
We report two clinical pregnancies occurring after intracytoplasmic sperm
injection (ICSI) using cryopreserved spermatozoa obtained from testicular
biopsy, made in two different infertility situations in our clinic. The
first patient showed a secretory azoospermia associated with elevated serum
follicular stimulating hormone (FSH) level and spermiogenesis maturation
arrest. The second patient was affected by azoospermia resulting from
bilateral epididymal obstruction. Spermatozoa present in the wet
preparation of testicular biopsy made on the day of scrotal exploration
were cryopreserved within the testicular tissue for both men.
Intracytoplasmic injections were performed at a later date, using
spermatozoa prepared from frozen-thawed tissues. In each case, three
embryos were obtained and transferred in utero. The transfers resulted in a
twin pregnancy for the first case, and in a singleton pregnancy for the
second. Living foetuses were seen in the ultrasound scan at the 7th week
and both pregnancies are proceeding to date beyond 30 weeks without
complications.
相似文献